Antimicrobial Stewardship Needs Indication-to-Stop Evidence, Not Use Dashboards Alone
Hospital antimicrobial stewardship programs increasingly receive standardized antibiotic-use dashboards, including days-of-therapy measures and the National Healthcare Safety Network Standardized Antimicrobial Administration Ratio. These measures are valuable for benchmarking, but they cannot by themselves show whether a course had a valid indication, whether microbiology results changed therapy, whether a time-out occurred, or why antibiotics were continued or stopped. This conceptual synthesis reviewed AlexandrAI graph context, CDC Core Elements, CDC NHSN AUR and SAAR materials, CDC resistance-burden sources, IDSA/SHEA implementation guidance, a Cochrane review of inpatient stewardship interventions, WHO stewardship and AWaRe materials, and rapid-diagnostics reviews. The paper contributes an Indication-to-Stop Accountability Chain with nine auditable stages from syndrome and empiric rationale through diagnostic response, action, duration, stop decision, and safety feedback. The key finding is practical: DOT and SAAR should remain exposure and benchmarking infrastructure, while clinical stewardship claims should be attached to documented decision points. Programs should therefore report the weakest verified stage of the antibiotic course when they claim appropriateness or action, rather than allowing use dashboards to imply clinical review.
Introduction
Antimicrobial stewardship has a measurement success problem. Hospitals can now submit standardized antimicrobial use data, view days-of-therapy rates, and compare modeled use through the Standardized Antimicrobial Administration Ratio, or SAAR. These instruments are real progress: they make exposure visible, benchmarkable, and easier to discuss across prescribers, pharmacists, infection prevention, and leadership [[cite:cdcAur,cdcSaar]].
The same instruments can also be overread. A course with fewer days is not automatically appropriate; a low benchmark does not prove the right antibiotic was chosen; a time-out checkbox does not prove that culture results were interpreted; and a rapid diagnostic result does not improve care unless someone changes or confirms therapy for a reason. CDC's AUR protocol is explicit that SAAR is not a definitive measure of appropriateness or judiciousness [[cite:cdcAur]].
This paper asks what evidence should sit between a use dashboard and a claim of clinical stewardship. The question matters because the stakes are not abstract. CDC's resistance-burden materials report more than 2.8 million antimicrobial-resistant infections and more than 35,000 deaths annually in the United States in the 2019 threats report, with pandemic-era increases in several hospital-onset resistant infections in later updates [[cite:cdcThreats]]. Yet urgency cannot justify weak evidence. Stewardship programs must reduce unnecessary exposure without delaying necessary therapy or damaging trust in infectious-disease review [[cite:davey2017]].
The contribution is an Indication-to-Stop Accountability Chain. It treats standardized use metrics as a necessary exposure layer, then adds auditable clinical links: indication, empiric rationale, diagnostic plan, review trigger, diagnostic interpretation, action, duration, stop decision, safety exception, and feedback. The proposed chain is not a new clinical guideline. It is a reporting model that calibrates what a hospital can claim from the evidence it actually records.
Methods
The study mode was conceptual synthesis. The internal graph search used six queries: antimicrobial stewardship de-escalation, antibiotic stewardship days of therapy, diagnostic timeout, antibiotic timeout, standardized antimicrobial administration ratio, and NHSN antimicrobial use. No prior AlexandrAI item was found on antimicrobial stewardship, antibiotic time-outs, NHSN AU, SAAR, or diagnostic stewardship; two unrelated graph results appeared for diagnostic stewardship because the terms overlapped with broader accountability subjects.
External searching used twelve targeted queries across official guidance, measurement protocols, professional guidelines, systematic reviews, and diagnostic-stewardship literature. The final full-read corpus included thirteen sources: CDC Core Elements, CDC AUR protocol, CDC SAAR guide, CDC resistance-burden material, CDC AUR resource index, IDSA/SHEA implementation guidance, the Davey Cochrane review, the Tamma Four Moments decision framing, Timbrook and Vardakas rapid-diagnostics reviews, the Peri network meta-analysis, and two WHO stewardship/AWaRe sources [[cite:cdcCore,cdcAur,cdcSaar,cdcThreats,cdcAurPage,idsaShea2016,davey2017,tamma2021,timbrook2017,vardakas2015,peri2024,whoToolkit,whoAware]].
Screening prioritized sources that could answer one of four questions: what program elements are expected, what use metrics actually measure, what intervention evidence supports action, and where the evidence warns against overclaiming. Sources were excluded when they were duplicative, too narrow for the central model, blocked from direct verification, or primarily legal/accreditation context rather than evidence about the antibiotic course.
What Use Dashboards Can And Cannot Prove
The NHSN AU Option is a standardized reporting infrastructure. Its primary metric is antimicrobial days per 1,000 days present, and an antimicrobial day is counted when any amount of a specific agent is administered to a particular patient on a calendar day. Data are reported in aggregate by month and location or facility-wide inpatient areas, with manual data entry unavailable for the AU Option [[cite:cdcAur]].
This definition is intentionally exposure-centered. It answers questions such as how many antimicrobial days were administered in a population, how use changes over time, and how use compares against a predicted benchmark. It does not know whether the patient had infection, whether sepsis risk required broad empiric therapy, whether a blood culture was contaminated, whether a susceptibility result arrived, whether the regimen was narrowed, or why therapy continued.
SAAR adds modeled comparison. CDC's AUR protocol defines SAAR as observed antimicrobial use divided by predicted antimicrobial use. The 2023 baseline guide describes the location types, antimicrobial categories, and risk-adjustment details used for those models [[cite:cdcAur,cdcSaar]]. This makes SAAR a powerful triage signal for investigation, but it stays a summary signal. CDC warns that SAAR alone is not a definitive appropriateness measure [[cite:cdcAur]].
The right conclusion is not that DOT or SAAR are weak. The right conclusion is that they are exposure and benchmarking tools. They should be used to find variation, prioritize review, and report program activity. The error is allowing them to stand in for the missing clinical ledger.
Intervention Evidence Points Toward Course-Level Action
CDC's Core Elements place action, tracking, reporting, and education beside leadership, accountability, and pharmacy expertise. The action element names prospective audit and feedback or preauthorization; the tracking element asks programs to monitor prescribing, intervention impact, and outcomes such as C. difficile and resistance; the reporting element asks for regular information back to prescribers, pharmacists, nurses, and leadership [[cite:cdcCore]].
IDSA/SHEA guidance is aligned. It recommends preauthorization and/or prospective audit and feedback over no such interventions, recommends shortest effective duration strategies, and prefers days of therapy over defined daily dose for use measurement. It also encourages programs to examine appropriateness against guidelines, particularly for targeted interventions [[cite:idsaShea2016]].
The Cochrane review supplies the main effect boundary. In randomized trial evidence, stewardship interventions reduced antibiotic treatment duration by 1.95 days from an 11.0-day baseline and did not increase mortality in aggregate. The review also found that enablement and restriction were associated with increased compliance, and that feedback strengthened enabling interventions [[cite:davey2017]]. These results support action, not passive measurement.
The same review prevents overcorrection. It reported low-certainty concerns that restrictive interventions may delay treatment or create negative professional culture when communication and trust fail [[cite:davey2017]]. IDSA/SHEA similarly treats time-outs and stop orders as weak, low-quality-evidence strategies unless prompting makes review happen [[cite:idsaShea2016]]. An accountability chain therefore has to record safety exceptions, not simply reward shorter durations.
The Indication-to-Stop Accountability Chain
The proposed chain reports the weakest verified stage of an antibiotic course. It starts with exposure metrics but does not stop there. A hospital can claim benchmarked use when DOT and SAAR are valid. It can claim reviewed use only when the review prompt and action record exist. It can claim diagnostic stewardship only when diagnostic results are linked to a therapy decision. It can claim appropriate stopping only when duration and stop rationale are recorded.
The chain deliberately separates observation from interpretation. DOT observes exposure. SAAR interprets exposure against a model. Indication and syndrome connect exposure to a clinical question. Diagnostics create new evidence. The review trigger forces a decision point. Action and duration show what changed. Safety and feedback protect patients from an excessively narrow program goal.
The chain also makes partial evidence usable. A hospital that has valid AU reporting but no course-level indication record can honestly say it benchmarks exposure. A hospital with audit notes but no diagnostic-result linkage can say it performs review, but not that diagnostics are reliably converted into therapy decisions. A hospital with stop dates but no safety review can say it manages duration, but not that shortened therapy has been monitored for harm.
Diagnostic Stewardship Is An Action Link, Not A Lab Speed Claim
Rapid diagnostics illustrate why the chain needs a result-to-action stage. Peri and colleagues' network meta-analysis of bloodstream infection diagnostics included 88 papers and 25,682 patient encounters. It found that rapid diagnostic testing plus stewardship was associated with lower mortality compared with conventional blood culture alone, and it shortened time to optimal therapy. The paper also reported substantial heterogeneity and a predominance of quasi-experimental designs [[cite:peri2024]].
The implication is not that every hospital should claim outcome gains from a new laboratory instrument. The implication is that the instrument's value depends on implementation. The same Peri analysis defined stewardship in this context as active implementation of diagnostic results through recommendations. Earlier rapid molecular diagnostic reviews likewise locate the decision-making value in how results change therapy, not merely in faster result availability [[cite:timbrook2017,vardakas2015]].
The Indication-to-Stop Chain therefore treats diagnostics as a hinge. Before the result, the empiric rationale should be explicit. After the result, the action should be explicit. If a culture is negative, contaminated, discordant with the clinical picture, or delayed, the record should say how the team interpreted that uncertainty. Without that hinge, a rapid-diagnostics dashboard risks repeating the same weakness as a use dashboard: measuring a useful process while leaving the clinical decision invisible.
Global Classification Still Needs Local Course Evidence
WHO stewardship and AWaRe materials widen the model beyond U.S. measurement infrastructure. WHO's practical toolkit supports core stewardship structures and resources for facility-level programs, especially in low- and middle-income settings. The AWaRe antibiotic book gives concise guidance on choice, dose, route, and duration for common infections and supports the Access, Watch, Reserve classification [[cite:whoToolkit,whoAware]].
AWaRe is valuable because it reminds programs that antibiotic days are not interchangeable. A day of a Reserve agent, a Watch agent, and a first-line Access agent carry different stewardship meanings. But AWaRe does not replace local indication, diagnostic, and stop evidence. A Watch antibiotic can be appropriate for a high-risk presentation; an Access antibiotic can still be unnecessary if there is no bacterial infection.
This is why the chain records both class and reason. Global classification helps sort and compare; local course evidence explains. The same reporting pattern can work in resource-rich and resource-constrained settings because it does not require every site to have the same electronic health record maturity. It requires the program to state which stage it can verify and which stage remains aspirational.
Discussion
The central finding is a claim-calibration rule: exposure dashboards should trigger stewardship investigation, not substitute for stewardship proof. CDC, NHSN, and IDSA/SHEA have already built much of the infrastructure. The missing step is to report the antibiotic course as a chain of auditable decisions, with the weakest verified stage visible.
This rule helps reconcile two truths. First, standardized measures are indispensable. Without DOT, days present, route, location, and SAAR, programs lack a common language for use. Second, aggregate use is clinically underdetermined. It cannot know whether a broad empiric start was necessary, whether the patient improved, whether a susceptibility result demanded narrowing, or whether stopping would have been unsafe.
The model is also a protection against performative time-outs. A time-out is useful when it creates a review moment that changes or justifies therapy. It is weak when it is only a checkbox. IDSA/SHEA's warning that time-outs and stop orders require prompting supports the design choice: the chain requires evidence of a prompt, an interpretation, and an action [[cite:idsaShea2016]].
Finally, the model keeps stewardship from becoming simple antibiotic minimization. The Davey review supports reducing unnecessary use, but it also identifies concerns around delay and professional culture for restrictive interventions [[cite:davey2017]]. Therefore, safety exceptions, treatment-failure signals, and prescriber feedback are not secondary paperwork. They are the parts of the chain that preserve stewardship as patient-centered optimization.
Implementation Requirements
A practical implementation can start with a small set of fields tied to the stewardship queue: syndrome, indication, empiric class, diagnostic plan, review due date, diagnostic result state, action, duration or stop date, and exception. These fields do not need to replace AU reporting; they sit beside it for sampled courses, high-SAAR categories, broad-spectrum agents, positive blood cultures, or targeted syndromes.
Programs should avoid turning the chain into a punitive form. The point is to make uncertainty visible. Valid actions include continuing therapy because cultures are pending and the patient is unstable, broadening therapy because new resistance evidence appears, stopping because bacterial infection is unlikely, narrowing because susceptibilities support it, or scheduling another review because evidence remains incomplete.
The chain can also guide data governance. Patient-level course records may be protected, but aggregate reporting can publish stage completion without exposing sensitive clinical details: percentage of broad-spectrum starts with documented indication, percentage with review by 72 hours, percentage with diagnostic-result action, percentage with planned duration, and percentage with safety follow-up. That makes the public claim stronger without publishing patient narratives.
Limitations
This paper is a conceptual synthesis, not a trial and not medical advice. It does not estimate the causal effect of the proposed reporting chain on mortality, resistance, length of stay, or C. difficile. The chain is an evidence-reporting model that must be tested prospectively.
The corpus is strongest for hospital stewardship, U.S. NHSN measurement, and bloodstream infection diagnostic examples. Outpatient stewardship, long-term care, pediatrics, oncology, surgery, and low-resource facilities may need modified fields and different thresholds. WHO sources support global adaptation, but local policy and clinical governance remain necessary [[cite:whoToolkit,whoAware]].
The model also depends on documentation quality. A structured field can be inaccurate, copied forward, or completed after the fact. For that reason, the chain should be paired with audit sampling, pharmacist or infectious-disease review, and feedback, not treated as self-validating data.
Finally, use dashboards can be updated faster than clinical evidence chains. A hospital may have clean AU data before it has indication and stop records. The model handles this by allowing partial claims, but users must resist reading a partial stage as a complete stewardship pathway.
Conclusion
Antimicrobial stewardship needs both exposure measurement and course-level evidence. DOT and SAAR can tell a hospital where to look, how use compares, and whether trends are moving. They cannot prove indication, diagnostic interpretation, de-escalation, duration, stop, or safety by themselves.
The Indication-to-Stop Accountability Chain gives programs a proportional reporting rule: publish the weakest verified stage when making stewardship claims. A program with dashboards can claim benchmarked exposure; a program with review notes can claim prompted review; a program with diagnostic-result action and duration records can claim a stronger form of stewardship. The research agenda is now empirical: test whether publishing this chain improves clinician feedback, reduces unnecessary therapy, protects timely treatment, and makes stewardship claims more trustworthy.